Comparative Pharmacology
Head-to-head clinical analysis: AXID AR versus PEPCID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXID AR versus PEPCID.
AXID AR vs PEPCID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nizatidine is a competitive, reversible inhibitor of histamine at the H2-receptors of the gastric parietal cells, reducing gastric acid secretion.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion by inhibiting cyclic AMP generation.
75 mg orally once daily at bedtime for heartburn relief; maximum 150 mg per 24 hours.
20 mg orally twice daily or 40 mg orally once daily at bedtime for duodenal ulcer; 40 mg orally once daily at bedtime for gastric ulcer; 20 mg orally once daily for GERD; 20 mg orally twice daily for erosive esophagitis; 20 mg intravenously every 12 hours for hospitalized patients with pathological hypersecretory conditions.
None Documented
None Documented
Terminal elimination half-life is 1.5–2.5 hours (mean ~2 hours) in patients with normal renal function. In elderly or those with creatinine clearance <50 mL/min, half-life may extend to 4–6 hours, necessitating dose adjustment.
Terminal elimination half-life: 2.5-3.5 hours in normal renal function; prolonged to 8-10 hours in moderate renal impairment (CrCl 10-50 mL/min) and 15-20 hours in severe impairment (CrCl <10 mL/min); no significant change in hepatic impairment.
Primarily renal; ~60% of an oral dose is excreted unchanged in urine via tubular secretion and glomerular filtration. Hepatic metabolism accounts for ~30% (N-oxidation, S-oxidation, and N-demethylation), with metabolites and small amounts of parent drug eliminated in feces via bile.
Renal: ~65-70% unchanged via tubular secretion (active) and glomerular filtration; hepatic metabolism (S-oxidation) ~30%; fecal: <5%.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist